The Journal of dermatological treatment最新文献_第6页

Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. 白癜风患者的抑郁和抑郁症状：来自横断面、基于人群的全球VALIANT调查的结果

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2504082

Khaled Ezzedine, Davinder Parsad, John E Harris, Nanja van Geel, Jackie Gardner, Kristen Bibeau, Jessy Gao, Haobo Ren, Iltefat H Hamzavi

{"title":"Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey.","authors":"Khaled Ezzedine, Davinder Parsad, John E Harris, Nanja van Geel, Jackie Gardner, Kristen Bibeau, Jessy Gao, Haobo Ren, Iltefat H Hamzavi","doi":"10.1080/09546634.2025.2504082","DOIUrl":"https://doi.org/10.1080/09546634.2025.2504082","url":null,"abstract":"Purpose: Vitiligo often affects quality of life and psychosocial well-being. This analysis of the population-based global Vitiligo and Life Impact Among International Communities (VALIANT) study sought to understand the impact of vitiligo on depression and depressive symptoms from the patient perspective.Materials and methods: The cross-sectional survey collected information on patient demographics, clinical characteristics, mental health diagnoses, and depressive symptoms (assessed using the Patient Health Questionnaire-Depression screener [PHQ-9]) among recruited patients who reported a vitiligo diagnosis.Results: Of 3541 VALIANT respondents, 24.5% reported formal diagnosis of depression, and 55.0% reported moderate-to-severe symptoms of depression per the PHQ-9. Rates of formally diagnosed depression and moderate-to-severe depressive symptoms were significantly higher in younger patients, those with Fitzpatrick skin types IV-VI (i.e. darker skin), >5% affected body surface area, hand or face involvement, and those receiving mental healthcare versus their counterparts (all p < 0.0001). Interestingly, moderate-to-severe depressive symptoms were more common among patients with shorter disease duration (≤2 vs 3-9 and ≥10 years; p < 0.01), but there was no correlation between diagnosed depression and disease duration.Conclusions: These VALIANT study findings highlight that depression may be common but often undiagnosed among patients with vitiligo, reinforcing the importance of an improved and multifaceted approach to vitiligo management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2504082"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis. 米诺地尔单独与米诺地尔联合低水平激光治疗雄激素性脱发的疗效比较：一项系统回顾和荟萃分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2024.2447355

Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi

{"title":"Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis.","authors":"Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi","doi":"10.1080/09546634.2024.2447355","DOIUrl":"10.1080/09546634.2024.2447355","url":null,"abstract":"Objective: This systematic review evaluates the efficacy of minoxidil alone versus minoxidil with low-level laser therapy (LLLT) for androgenic alopecia.Study design: systematic review and meta-analysis.Methods: An online search of PubMed, Web of Science, and MEDLINE was conducted. Randomized clinical trials comparing minoxidil monotherapy with minoxidil and LLLT combination therapy were included based on predefined criteria. The Risk of Bias 2.0 (RoB 2.0) tool was used for quality assessment.Results: From 38 identified studies, 34 remained after excluding 4 duplicates. Further exclusions left 4 eligible studies comparing minoxidil alone with minoxidil and LLLT. The meta-analysis found no statistically significant differences in hair counts between the two groups at baseline, 12 weeks, and 8 weeks post-treatment [mean difference = -0.04, 95% CI -1.22 to 1.14, p = .95, I² = 0%]. Similarly, hair diameter showed no significant differences at the same time points [mean difference = 0.00, 95% CI -0.00 to 0.00, p = .98, I² = 38%].Conclusion: The combination of minoxidil and LLLT does not significantly improve outcomes compared to minoxidil alone for treating androgenic alopecia.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447355"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis. 儿童特应性皮炎患者的转诊、评估和管理模式在变态反应学和皮肤科的差异。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-09 DOI: 10.1080/09546634.2025.2515495

Nicole L Edmonds, Courtney E Heron, Monica G Lawrence, Barrett Zlotoff

{"title":"Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis.","authors":"Nicole L Edmonds, Courtney E Heron, Monica G Lawrence, Barrett Zlotoff","doi":"10.1080/09546634.2025.2515495","DOIUrl":"https://doi.org/10.1080/09546634.2025.2515495","url":null,"abstract":"Introduction: Allergists and dermatologists often take different approaches to caring for pediatric patients with atopic dermatitis (AD).Methods: A retrospective chart review was performed on patients <18 years old treated for AD within the University of Virginia health system from 2015 to 2020. Data were collected on patient and referring provider demographics as well as initial visit evaluation and management.Results: A total of 269 patients presented to allergy, 685 patients presented to dermatology, and 14 patients presented to a combined allergy-dermatology clinic as an initial visit with a primary diagnosis of AD. Both specialties were most often referred to by a generalist though dermatology received more specialty provider referrals. In addition, allergy ordered more diagnostic testing (IgE, allergens, complete blood count), while dermatology prescribed more medications (topical corticosteroids, topical calcineurin inhibitors, immunosuppressants). Patients seen in the combined dermatology-allergy clinic were more likely to receive diagnostic testing than patients seen in dermatology clinic and were more likely to be prescribed medications than patients seen in allergy clinic.Conclusions: Our findings suggest allergists may focus more on identifying triggers of AD, while dermatologists largely focus on the prescription of therapies. Clinical care may be more comprehensive when allergists and dermatologists work synergistically.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2515495"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of quality of life and economic burden in patients with chronic urticaria: a comparative study of spontaneous and induced urticaria and its effects on cognition of biologics. 慢性荨麻疹患者的生活质量和经济负担分析：自发性和诱发性荨麻疹的比较研究及其对生物制剂认知的影响。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/09546634.2025.2506672

Shixi Ma, Zixuan Wang, Yaxin Zhang, Guan Jiang

{"title":"Analysis of quality of life and economic burden in patients with chronic urticaria: a comparative study of spontaneous and induced urticaria and its effects on cognition of biologics.","authors":"Shixi Ma, Zixuan Wang, Yaxin Zhang, Guan Jiang","doi":"10.1080/09546634.2025.2506672","DOIUrl":"10.1080/09546634.2025.2506672","url":null,"abstract":"Objective: To compare and analyze the quality of life, economic burden, and knowledge about biological agents between chronic spontaneous urticaria (CSU) and chronic induced urticaria (ClndU), and to provide a reference for clinical rational drug use and patient classification management.Methods: This cross-sectional multicenter study involved 386 chronic urticaria (CU) patients from three hospitals in various regions, seen between November 2024 and April 2025. Data on demographics, clinical characteristics, Dermatological Quality of Life Index (DLQI), economic burden, and knowledge about biological agents were collected.Results: 228 CSU patients and 158 CIndU patients. CSU patients had higher DLQI score than CIndU patients (p < .05). CU type, comorbidities, and urticaria control test score were identified as factors affecting the quality of life of CU patients. CSU patients had higher outpatient costs compared to CIndU patients (p < .05). CU type, insurance type, comorbidities, and disease duration were factors influencing outpatient costs. CSU patients exhibited better understanding of relapse and complete remission compared to CIndU patients (p < .05).Conclusion: Notable differences exist between CSU and CIndU patients in terms of quality of life, economic impact, and knowledge about biological agents. Therefore, it is necessary to categorize these patients to enhance their understanding and utilization of biological agents.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2506672"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 使用upadacitinib治疗中重度特应性皮炎：患者分析，剂量选择和治疗调节，现实生活教给我们什么？

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-09 DOI: 10.1080/09546634.2025.2509541

Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo

{"title":"Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?","authors":"Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo","doi":"10.1080/09546634.2025.2509541","DOIUrl":"10.1080/09546634.2025.2509541","url":null,"abstract":"Purpose: This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods: A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monotherapy. Clinical outcomes were evaluated up to 104 weeks using Eczema Area and Severity Index (EASI), itch and sleep numeric rating scale (NRS), and Dermatology Life Quality Index (DLQI).Results: Both dosages led to significant and sustained improvements in disease severity, pruritus, sleep disturbances, and quality of life, with 77.8% achieving EASI 75 and 39.2% achieving EASI 100 at week 16. Responses were similar between doses, although long-term itch control was better in the 30 mg group. Higher baseline EASI score was a positive predictor of response, while head and neck involvement and prior systemic treatments, particularly cyclosporine, were associated with poorer outcomes. The safety profile was consistent with prior reports, with acneiform eruption, elevated creatine phosphokinase (CPK), and dyslipidemia being the most common adverse events. No reactivation of atopic keratoconjunctivitis was observed.Conclusions: These findings support the efficacy, safety, and flexibility of upadacitinib dosing in clinical practice.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2509541"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib. upadacitinib治疗成人稳定型非节段性白癜风10例临床观察。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-02 DOI: 10.1080/09546634.2025.2492879

Mingzhu Yuan, Ruyi Li, Wen Zhang, Yi Sun

{"title":"Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib.","authors":"Mingzhu Yuan, Ruyi Li, Wen Zhang, Yi Sun","doi":"10.1080/09546634.2025.2492879","DOIUrl":"https://doi.org/10.1080/09546634.2025.2492879","url":null,"abstract":"Objective: To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.Methods: Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.Results: A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.Conclusion: Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2492879"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy analysis of blunt separation combined with uncrosslinked sodium hyaluronate compound solution injection for sunken upper eyelid treatment in Asians. 钝性分离联合非交联透明质酸钠复合溶液注射治疗亚洲人上睑凹陷的疗效分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-29 DOI: 10.1080/09546634.2025.2497370

Qingmei Jin, Richeng Dong, Jiahui Zhi, Weilu Xu, Zhehu Jin, Chenglong Jin

{"title":"Efficacy analysis of blunt separation combined with uncrosslinked sodium hyaluronate compound solution injection for sunken upper eyelid treatment in Asians.","authors":"Qingmei Jin, Richeng Dong, Jiahui Zhi, Weilu Xu, Zhehu Jin, Chenglong Jin","doi":"10.1080/09546634.2025.2497370","DOIUrl":"https://doi.org/10.1080/09546634.2025.2497370","url":null,"abstract":"Aim of the study: Injectable fillers are a popular treatment for sunken upper eyelid (SUE) deformity, but their efficacy and duration are limited. This study evaluated the clinical efficacy and safety of blunt separation combined with an uncrosslinked sodium hyaluronate compound solution for treating SUE in Asians.Methods: Twenty-seven Chinese patients (22 women, five men) with SUE underwent blunt separation to loosen subcutaneous adhesions. After disrupting the dermal layer, an uncrosslinked sodium hyaluronate solution was injected to stimulate collagen regeneration. Symptom improvement, recurrence, safety, and patient satisfaction were assessed.Results: Park S grading scores significantly improved after-treatment, 6 months, and 1 year (p < 0.05) immediately. Patients experienced mild pain, erythema, and swelling. Four had post-treatment bruising, which resolved within 5-8 days. No other adverse events or recurrences were observed, and patient satisfaction was high.Conclusions: This single-arm trial suggests that blunt separation with uncrosslinked sodium hyaluronate is a safe and effective SUE treatment with minimal side effects, the findings indicate potential for clinical application.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2497370"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reshaping treatment paradigm in actinic keratosis by using a modified Delphi questionnaire. 用改进的德尔菲问卷重塑光化性角化病的治疗范式。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-14 DOI: 10.1080/09546634.2025.2487657

Thomas Dirschka, Marco Ardigò, Maria Concetta Fargnoli, Carla Ferrándiz-Pulido, Yolanda Gilaberte, Ina Hadshiew, Ketty Peris, Rolf-Markus Szeimies

{"title":"Reshaping treatment paradigm in actinic keratosis by using a modified Delphi questionnaire.","authors":"Thomas Dirschka, Marco Ardigò, Maria Concetta Fargnoli, Carla Ferrándiz-Pulido, Yolanda Gilaberte, Ina Hadshiew, Ketty Peris, Rolf-Markus Szeimies","doi":"10.1080/09546634.2025.2487657","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487657","url":null,"abstract":"Purpose: Actinic keratosis (AK) is the main precursor of invasive cutaneous squamous cell carcinoma (cSCC). Since it is impossible to predict which lesions will progress to cSCC, early treatment of AK is crucial. Although AK treatments are effective, some are associated with local skin reactions that may impact treatment compliance and effectiveness. The aim of this modified Delphi study was to review the efficacy and safety of the different AK treatments, gain an understanding of the dermatologists' perspectives on their use, and provide guidelines for clinical practice.Materials and methods: This document corresponds to a modified Delphi consensus survey, based on a literature review and a single round of questionnaire.Results: The Delphi questionnaire was completed by 73 dermatologists from Germany, Italy, and Spain. Agreement was achieved for 78% of statements, while 11% showed discrepancies or were rejected.Conclusions: Key findings emphasize the importance of patient-centered approaches and treatment attributes beyond efficacy (e.g. tolerability or adherence). Understanding the mechanisms of action of treatments is vital for managing patients' and clinicians' expectations and optimizing outcomes. Alternative strategies for evaluating efficacy, including the Actinic Keratosis Area and Severity Index (AKASI) score and lesion reduction from baseline, were also highlighted.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487657"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants? 胶体燕麦是预防和治疗婴儿特应性皮炎的有效润肤成分吗？

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-21 DOI: 10.1080/09546634.2025.2487945

Joseph F Fowler, Lin Ma, James Bergman, Paul Horowitz, Tina Lavender, Lawrence F Eichenfield, Zoe Draelos, Simon G Danby, Michael J Cork

{"title":"Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?","authors":"Joseph F Fowler, Lin Ma, James Bergman, Paul Horowitz, Tina Lavender, Lawrence F Eichenfield, Zoe Draelos, Simon G Danby, Michael J Cork","doi":"10.1080/09546634.2025.2487945","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487945","url":null,"abstract":"Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by barrier dysfunction and immune dysregulation, often leading to increased allergen penetration, sensitization, and secondary infections. Colloidal oat emollients are widely used in adult AD management, but their role in pediatric AD treatment, prevention, and allergy modulation remains under investigation.Methods: A comprehensive literature review evaluated clinical and preclinical studies on colloidal oat-containing emollients in pediatric AD treatment and prevention. Studies assessing skin barrier function, immune modulation, AD prevention, food allergy risk, and healthcare utilization were included.Results: Colloidal oat emollients improved skin hydration, reduced transepidermal water loss (TEWL), and supported barrier repair, leading to fewer AD flares and reduced reliance on steroid treatments. Studies suggest that early, consistent use of advanced emollient formulations may lower AD incidence in high-risk infants and reduce food sensitization rates. Real-world data indicate that patients using colloidal oat emollients have fewer clinic visits and lower overall healthcare costs. Concerns about oat sensitization remain unsubstantiated in most studies.Conclusion: Colloidal oat emollients are effective, well-tolerated, and cost-efficient for pediatric AD management. Their barrier-restorative and anti-inflammatory properties may reduce AD and allergy risk. Future research should focus on head-to-head emollient comparisons to optimize treatment strategies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487945"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy analysis of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus in women of childbearing age. 5-氨基乙酰丙酸光动力治疗育龄妇女外阴硬化性地衣的疗效分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-06 DOI: 10.1080/09546634.2025.2497362

Lijuan Yang, Qian Shang, Dongning Zhu, Yu Jia, Chunyu Shi, Yanling Dang

{"title":"Efficacy analysis of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus in women of childbearing age.","authors":"Lijuan Yang, Qian Shang, Dongning Zhu, Yu Jia, Chunyu Shi, Yanling Dang","doi":"10.1080/09546634.2025.2497362","DOIUrl":"https://doi.org/10.1080/09546634.2025.2497362","url":null,"abstract":"Objective: To investigate the efficacy and long-term durability of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in treating vulvar lichen sclerosus (VLS) in women of childbearing age.Methods: Fifty-five patients with VLS who had failed long-term repeated pharmacological treatments (mean disease duration: 3.6 ± 1.4 years)were enrolled. All participants underwent four sessions of ALA-PDT. Follow-up evaluations were conducted for six months after treatment. Outcomes were assessed using the Cattaneo clinical symptom and sign score and the Dermatology Life Quality Index (DLQI) questionnaire at baseline, after four treatments, and at 3-6 months post-treatment.Results: At the 6-month follow-up, efficacy rates were 81.8% for pruritus relief, 67.3% for skin elasticity restoration, 63.6% for skin color improvement, and 72.7% for lesion area reduction. Pain was the only reported adverse reaction during treatment.Conclusion: 20% ALA-PDT is a safe, effective, and durable therapeutic option for VLS with minimal side effects. Notably, it provides a viable alternative for patients unresponsive to conventional therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2497362"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0